68Ga-PSMA-11与18F-PSMA-1007 PET/CT配对比较:生化复发前列腺癌的陷阱频率与检测效能
该回顾性配对研究纳入102例根治性前列腺切除术后生化复发患者,比较68Ga-PSMA-11与18F-PSMA-1007 PET/CT。18F-PSMA-1007显示良性来源摄取灶约5倍于68Ga-PSMA-11(245 vs 52),且良性灶SUVmax显著更高(P<0.0001),但两者归因于复发的病灶数相似。
要点
- 18F-PSMA-1007的良性摄取灶显著多于68Ga-PSMA-11,需警惕假阳性。
- 两者检测到的复发灶数量相似,但18F-PSMA-1007良性灶SUVmax更高。
- 阅片需加强已知陷阱培训并结合CT等临床信息鉴别。
核心结论
- 18F-PSMA-1007 PET显示良性来源PSMA摄取灶的数量远高于68Ga-PSMA-11 PET,提示需加强阅片培训并结合临床背景报告。
研究设计与样本
- 回顾性配对研究,纳入102例根治性前列腺切除术后生化复发患者,行18F-PSMA-1007 PET/CT,并按临床变量匹配相应68Ga-PSMA-11 PET/CT,共204次扫描由1名核医学医师审阅。
主要发现
- 18F-PSMA-1007 PET与68Ga-PSMA-11 PET分别显示369和178个PSMA配体阳性病灶。
- 18F-PSMA-1007 PET良性来源病灶约5倍于68Ga-PSMA-11 PET(245 vs 52)。
- 良性病灶最常见为神经节、非特异性淋巴结和骨病灶,18F-PSMA-1007 PET中分别占43%、31%、24%,68Ga-PSMA-11 PET中分别占29%、42%、27%。
- 良性来源病灶SUVmax在18F-PSMA-1007 PET显著更高(P<0.0001)。
- 归因于复发前列腺癌的病灶数相似(18F-PSMA-1007 PET为124/369,68Ga-PSMA-11 PET为126/178)。
临床怎么用
- 使用18F-PSMA-1007 PET/CT时,应警惕神经节、非特异性淋巴结和骨等良性摄取陷阱,结合CT特征和临床背景鉴别,避免误判为复发。
局限性
- 回顾性设计,仅由1名核医学医师审阅所有PET/CT扫描。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has several principal advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency of non-tumor-related uptake and the detection efficacy comparing 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients. Methods: The study included 102 patients with biochemically recurrent PC after radical prostatectomy undergoing 18F-PSMA-1007 PET/CT imaging. On the basis of various clinical variables, patients with corresponding 68Ga-PSMA-11 PET/CT scans were matched. All PET/CT scans (n = 204) were reviewed by 1 nuclear medicine physician. First, all PET-positive lesions were noted. Then, lesions suspected of being recurrent PC were differentiated from lesions attributed to a benign origin on the basis of known pitfalls and information from CT. For each region, the SUVmax of the lesion with the highest PSMA-ligand uptake was noted. Detection rates were determined, and SUVmax was compared separately for 68Ga-PSMA-11 and 18F-PSMA-1007. Results: In total, 18F-PSMA-1007 PET and 68Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-positive lesions, respectively. 18F-PSMA-1007 PET revealed approximately 5 times more lesions attributed to a benign origin than did 68Ga-PSMA-11 PET (245 vs. 52 lesions, respectively). The benign lesions most frequently observed were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for 18F-PSMA-1007 PET and 29%, 42%, and 27% for 68Ga-PSMA-11 PET, respectively. The SUVmax of lesions attributed to a benign origin was significantly higher (P < 0.0001) for 18F-PSMA-1007 PET. Further, a similar number of lesions was attributed to recurrent PC (124/369 for 18F-PSMA-1007 PET and 126/178 for 68Ga-PSMA-11 PET). Conclusion: The number of lesions with increased PSMA-ligand uptake attributed to a benign origin is considerably higher for 18F-PSMA-1007 PET than for 68Ga-PSMA-11 PET. This finding indicates the need for sophisticated reader training emphasizing known pitfalls and reporting within the clinical context.
引用
- Rauscher I, Krönke M, König M, et al. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2019. PMID: 31253741. doi:10.2967/jnumed.119.229187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。